MAIA Biotechnology Reports $6.37 Million Net Loss and $34.41 Million Cash Reserves in Latest 10-Q

MAIA Biotechnology, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company recorded a net loss of $6.37 million, an increase of 41% from the $4.52 million loss reported in the same period last year. Total operating expenses rose to $6.95 million, up 28% from $5.43 million in the prior year, primarily driven by a 54% increase in general and administrative expenses, which reached $3.42 million. Research and development expenses also saw a 10% increase, totaling $3.53 million, reflecting ongoing investments in clinical trials and related activities.

In terms of liquidity, MAIA Biotechnology experienced a substantial increase in cash reserves, ending the quarter with $34.41 million, compared to $10.86 million at the end of the previous fiscal year. This increase was largely attributed to a successful confidentially marketed public offering, where the company raised approximately $30 million by selling 20 million shares at $1.50 each. The company also reported net cash provided by financing activities of $31.05 million for the quarter, a significant rise from $5.46 million in the same quarter of 2025.

Operationally, MAIA Biotechnology is advancing its lead product candidate, ateganosine, through various clinical trials. The company has initiated a Phase 3 pivotal trial (THIO-104) for non-small cell lung cancer (NSCLC) and is expanding its Phase 2 trial (THIO-101) into the U.S. market, which is expected to enhance patient recruitment. As of March 31, 2026, the company had 44 active clinical trial sites across six countries, with plans to open additional sites in the U.S. to broaden its patient base.

The filing also highlighted strategic developments, including the establishment of partnerships with major pharmaceutical companies like Regeneron and BeOne Medicines for clinical trials involving ateganosine. These collaborations are expected to facilitate the development of ateganosine in combination with other therapies, potentially enhancing its efficacy in treating various cancers. The company is also exploring additional cancer indications beyond NSCLC, including hepatocellular carcinoma, colorectal cancer, and small cell lung cancer.

Looking ahead, MAIA Biotechnology anticipates continued operational losses as it invests in research and development. The company remains focused on securing additional funding to support its clinical programs and operational needs. Management expressed optimism about the potential for ateganosine to receive accelerated approval from the FDA based on the clinical data generated from ongoing trials, which could significantly impact the company's future financial performance and market position.